Academic Journal
Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors
| العنوان: | Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors |
|---|---|
| المؤلفون: | Orozco-Moreno, Margarita, Visser, Eline A, Hodgson, Kirsty, Hipgrave Ederveen, Agnes L, Bastian, Kayla, Goode, Emily Archer, Öztürk, Özden, Pijnenborg, Johan F A, Eerden, Nienke, Moons, Sam J, Rossing, Emiel, Wang, Ning, de Haan, Noortje, Büll, Christian, Boltje, Thomas J, Munkley, Jennifer |
| المساهمون: | Dutch Research Council (NWO) Veni, ERC-Stg, Prostate Cancer UK and the Bob Willis Fund through Research Innovation Awards, Prostate Cancer Research and the Mark Foundation |
| المصدر: | Glycobiology ; volume 33, issue 12, page 1155-1171 ; ISSN 1460-2423 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2023 |
| الوصف: | Aberrant glycosylation is a hallmark of cancer and is not just a consequence, but also a driver of a malignant phenotype. In prostate cancer, changes in fucosylated and sialylated glycans are common and this has important implications for tumor progression, metastasis, and immune evasion. Glycans hold huge translational potential and new therapies targeting tumor-associated glycans are currently being tested in clinical trials for several tumor types. Inhibitors targeting fucosylation and sialylation have been developed and show promise for cancer treatment, but translational development is hampered by safety issues related to systemic adverse effects. Recently, potent metabolic inhibitors of sialylation and fucosylation were designed that reach higher effective concentrations within the cell, thereby rendering them useful tools to study sialylation and fucosylation as potential candidates for therapeutic testing. Here, we investigated the effects of global metabolic inhibitors of fucosylation and sialylation in the context of prostate cancer progression. We find that these inhibitors effectively shut down the synthesis of sialylated and fucosylated glycans to remodel the prostate cancer glycome with only minor apparent side effects on other glycan types. Our results demonstrate that treatment with inhibitors targeting fucosylation or sialylation decreases prostate cancer cell growth and downregulates the expression of genes and proteins important in the trajectory of disease progression. We anticipate our findings will lead to the broader use of metabolic inhibitors to explore the role of fucosylated and sialylated glycans in prostate tumor pathology and may pave the way for the development of new therapies for prostate cancer. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/glycob/cwad085 |
| DOI: | 10.1093/glycob/cwad085/53667727/cwad085.pdf |
| الاتاحة: | http://dx.doi.org/10.1093/glycob/cwad085 https://academic.oup.com/glycob/advance-article-pdf/doi/10.1093/glycob/cwad085/53667727/cwad085.pdf https://academic.oup.com/glycob/article-pdf/33/12/1155/56698439/cwad085.pdf |
| Rights: | https://creativecommons.org/licenses/by/4.0/ |
| رقم الانضمام: | edsbas.E28A3DE5 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/glycob/cwad085 |
|---|